I-SPY 2-A Glimpse of the Future of Phase 2 Drug Development?

被引:36
作者
Harrington, David [1 ]
Parmigiani, Giovanni
机构
[1] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
CLINICAL-TRIALS;
D O I
10.1056/NEJMp1602256
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
[No abstract available]
引用
收藏
页码:7 / 9
页数:3
相关论文
共 5 条
[1]
[Anonymous], 2010, GUID IND AD DES CLIN
[2]
[Anonymous], 2007, REFL PAP METH ISS CO
[3]
Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].
Betensky, RA ;
Louis, DN ;
Cairncross, JG .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499
[4]
Box G.E., 1987, Empirical Model-Building and Response Surfaces, Vfirst
[5]
Multi-arm clinical trials of new agents: Some design considerations [J].
Freidlin, Boris ;
Korn, Edward L. ;
Gray, Robert ;
Martin, Alison .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4368-4371